An Interpretation of CSCO/ASCO International Guideline of Chemotherapy in Combination with Radiotherapy for Definitive-intent Treatment of Stage Ⅱ-Ⅳa Nasopharyngeal Carcinoma in 2021

ZHOU Yajuan; MOU Yanhua; HU Desheng

doi:10.3971/j.issn.1000-8578.2021.21.0163

Cancer Research on Prevention and Treatment > 2021 > 48(5): 553-562. > DOI: 10.3971/j.issn.1000-8578.2021.21.0163

ZHOU Yajuan, MOU Yanhua, HU Desheng. An Interpretation of CSCO/ASCO International Guideline of Chemotherapy in Combination with Radiotherapy for Definitive-intent Treatment of Stage Ⅱ-Ⅳa Nasopharyngeal Carcinoma in 2021[J]. Cancer Research on Prevention and Treatment, 2021, 48(5): 553-562. DOI: 10.3971/j.issn.1000-8578.2021.21.0163

Citation:

PDF (4704 KB)

An Interpretation of CSCO/ASCO International Guideline of Chemotherapy in Combination with Radiotherapy for Definitive-intent Treatment of Stage Ⅱ-Ⅳa Nasopharyngeal Carcinoma in 2021

Department of Radiotherapy, Hubei Cancer Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430079, China

Funding:

National Natural Science Foundation of China 81803065

More Information

Corresponding author:
HU Desheng, E-mail: hds_005@163.com
^*: Contributed Equally as the First Author
Received Date: February 09, 2021
Revised Date: March 08, 2021
Available Online: January 12, 2024

Graphical Abstract

Abstract

Abstract

Radiotherapy combined with chemotherapy is the main treatment for stage Ⅱ-Ⅳa nasopharyngeal carcinoma (NPC). In the era of intensity-modulated radiation therapy, the timing and implementation of chemotherapy are still controversial. In the past, the clinical guidelines for NPC generally described the specific radiotherapy technology, dose fractionation and the specific scheme of combined application of radiotherapy and chemotherapy, and may lack specific practical guidance. The joint international guidelines for NPC by CSCO and ASCO elaborates the mode and specific implementation recommendations of radical chemoradiotherapy for stage Ⅱ-Ⅳa NPC. This article aims to interpret the specific details of the guideline.
- Nasopharyngeal carcinoma,
- Radiotherapy,
- Concurrent chemoradiotherapy,
- Induction chemotherapy,
- Guideline

FullText(HTML)

Competing interests: The authors declare that they have no competing interests.

References (62)

References

[1]	Bray F, Ferlay J, Soerjomataram I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2018, 68(6): 394-424. doi: 10.3322/caac.21492
[2]	Chen YP, Ismaila N, Chua MLK, et al. Chemotherapy in Combination With Radiotherapy for Definitive-Intent Treatment of Stage Ⅱ-IVA Nasopharyngeal Carcinoma: CSCO and ASCO Guideline[J]. J Clin Oncol, 2021, 39(7): 840-859. doi: 10.1200/JCO.20.03237
[3]	Peng G, Wang T, Yang KY, et al. A prospective, randomized study comparing outcomes and toxicities of intensity-modulated radiotherapy vs. conventional twodimensional radiotherapy for the treatment of nasopharyngeal carcinoma[J]. Radiother Oncol, 2012, 104(3): 286-293. doi: 10.1016/j.radonc.2012.08.013
[4]	Kam MK, Leung SF, Zee B, et al. Prospective randomized study of intensity-modulated radiotherapy on salivary gland function in early-stage nasopharyngeal carcinoma patients[J]. J Clin Oncol, 2007, 25(31): 4873-4879. doi: 10.1200/JCO.2007.11.5501
[5]	Pow EH, Kwong DL, McMillan AS, et al. Xerostomia and quality of life after intensity-modulated radiotherapy vs. conventional radiotherapy for early-stage nasopharyngeal carcinoma: Initial report on a randomized controlled clinical trial[J]. Int J Radiat Oncol Biol Phys, 2006, 66(4): 981-991. doi: 10.1016/j.ijrobp.2006.06.013
[6]	Luo MS, Huang GJ, Liu HB. Oncologic outcomes of IMRT versus CRT for nasopharyngeal carcinoma: Ameta-analysis[J]. Medicine (Baltimore), 2019, 98(24): e15951. doi: 10.1097/MD.0000000000015951
[7]	Du T, Xiao J, Qiu Z, et al. The effectiveness of intensity-modulated radiation therapy versus 2D-RT for the treatment of nasopharyngeal carcinoma: A systematic review and meta-analysis[J]. PLoS One, 2019, 14(7): e0219611. doi: 10.1371/journal.pone.0219611
[8]	Co J, Mejia MB, Dizon JM. Evidence on effectiveness of intensity-modulated radiotherapy versus 2-dimensional radiotherapy in the treatment of nasopharyngeal carcinoma: Meta-analysis and a systematic review of the literature[J]. Head Neck, 2016, 38 suppl 1: E2130-E2142. http://europepmc.org/abstract/med/25546181
[9]	Al-Sarraf M, LeBlanc M, Giri PG, et al. Chemoradiotherapy versus radiotherapy in patients with advanced nasopharyngeal cancer: Phase Ⅲ randomized Intergroup study 0099[J]. J Clin Oncol, 1998, 16(4): 1310-1317. doi: 10.1200/JCO.1998.16.4.1310
[10]	Lee N, Harris J, Garden AS, et al. Intensity-modulated radiation therapy with or without chemotherapy for nasopharyngeal carcinoma: Radiation Therapy Oncology Group Phase Ⅱ trial 0225[J]. J Clin Oncol, 2009, 27(22): 3684-3690. doi: 10.1200/JCO.2008.19.9109
[11]	Lee AW, Ngan RK, Tung SY, et al. Preliminary results of trial NPC-0501 evaluating the therapeutic gain by changing from concurrent-adjuvant to inductionconcurrent chemoradiotherapy, changing from fluorouracil to capecitabine, and changing from conventional to accelerated radiotherapy fractionation in patients with locoregionally advanced nasopharyngeal carcinoma[J]. Cancer, 2015, 121(8): 1328-1338. doi: 10.1002/cncr.29208
[12]	Yang H, Chen X, Lin S, et al. Treatment outcomes after reduction of the target volume of intensity-modulated radiotherapy following induction chemotherapy in patients with locoregionally advanced nasopharyngeal carcinoma: A prospective, multi-center, randomized clinical trial[J]. Radiother Oncol, 2018, 126(1): 37-42. doi: 10.1016/j.radonc.2017.07.020
[13]	Ou X, Miao Y, Wang X, et al. The feasibility analysis of omission of elective irradiation to level IB lymph nodes in low-risk nasopharyngeal carcinoma based on the 2013 updated consensus guideline for neck nodal levels[J]. Radiat Oncol, 2017, 12(1): 137. doi: 10.1186/s13014-017-0869-x
[14]	Zhang F, Cheng YK, Li WF, et al. Investigation of the feasibility of elective irradiation to neck level Ib using intensity-modulated radiotherapy for patients with nasopharyngeal carcinoma: A retrospective analysis[J]. BMC Cancer, 2015, 15: 709. doi: 10.1186/s12885-015-1669-z
[15]	Co JL, Mejia MBA, Dizon JMR. Evidence on effectiveness of upper neck irradiation versus whole neck irradiation as elective neck irradiation in node-negative nasopharyngeal cancer: A meta-analysis[J]. J Glob Oncol, 2018, 4: 1-11.
[16]	Li JG, Yuan X, Zhang LL, et al. A randomized clinical trial comparing prophylactic upper versus whole-neck irradiation in the treatment of patients with nodenegative nasopharyngeal carcinoma[J]. Cancer, 2013, 119(17): 3170-3176. doi: 10.1002/cncr.28201
[17]	Gao Y, Zhu G, Lu J, et al. Is elective irradiation to the lower neck necessary for N0 nasopharyngeal carcinoma[J]. Int J Radiat Oncol Biol Phys, 2010, 77(5): 1397-1402. doi: 10.1016/j.ijrobp.2009.06.062
[18]	Tang LL, Tang XR, Li WF, et al. The feasibility of contralateral lower neck sparing intensity modulation radiated therapy for nasopharyngeal carcinoma patients with unilateral cervical lymph node involvement[J]. Oral Oncol, 2017, 69: 68-73. doi: 10.1016/j.oraloncology.2017.03.010
[19]	Xiao F, Dou S, Li Y, et al. Omitting the lower neck and sparing the glottic larynx in node-negative nasopharyngeal carcinoma was safe and feasible, and improved patient-reported voice outcomes[J]. Clin Transl Oncol, 2019, 21(6): 781-789. doi: 10.1007/s12094-018-1988-z
[20]	Chen QY, Wen YF, Guo L, et al. Concurrent chemoradiotherapy vs radiotherapy alone in stage Ⅱ nasopharyngeal carcinoma: Phase Ⅲ randomized trial[J]. J Natl Cancer Inst, 2011, 103(23): 1761-1770. doi: 10.1093/jnci/djr432
[21]	Wang S, Li S, Shen L. Combined chemoradiation vs radiation therapy alone in stage-Ⅱ nasopharyngeal carcinoma: A meta-analysis of the published literature[J]. Curr Probl Cancer, 2018, 42(3): 302-318. doi: 10.1016/j.currproblcancer.2018.03.004
[22]	Liu F, Jin T, Liu L, et al. The role of concurrent chemotherapy for stageⅡ nasopharyngeal carcinoma in the intensity-modulated radiotherapy era: A systematic review and meta-analysis[J]. PLoS One, 2018, 13(3): e0194733. doi: 10.1371/journal.pone.0194733
[23]	Xu C, Zhang LH, Chen YP, et al. Chemoradiotherapy versus radiotherapy alone in stageⅡ nasopharyngeal carcinoma: A systemic review and meta-analysis of 2138 patients[J]. J Cancer, 2017, 8(2): 287-297. doi: 10.7150/jca.17317
[24]	Huang X, Chen X, Zhao C, et al. Adding concurrent chemotherapy to intensity-modulated radiotherapy does not improve treatment outcomes for stageⅡ nasopharyngeal carcinoma: A phase 2 multicenter clinical trial[J]. Front Oncol, 2020, 10: 1314. doi: 10.3389/fonc.2020.01314
[25]	Tang C, Wu F, Wang R, et al. Comparison between nedaplatin and cisplatin plus docetaxel combined with intensity-modulated radiotherapy for locoregionally advanced nasopharyngeal carcinoma: A multicenter randomized phaseⅡ clinical trial[J]. Am J Cancer Res, 2016, 6(9): 2064-2075. http://europepmc.org/articles/PMC5043115/?report=classic
[26]	Wu X, Huang PY, Peng PJ, et al. Long-term follow-up of a phase Ⅲ study comparing radiotherapy with or without weekly oxaliplatin for locoregionally advanced nasopharyngeal carcinoma[J]. Ann Oncol, 2013, 24(8): 2131-2136. doi: 10.1093/annonc/mdt163
[27]	Blanchard P, Lee A, Marguet S, et al. Chemotherapy and radiotherapy in nasopharyngeal carcinoma: An update of the MAC-NPC meta-analysis[J]. Lancet Oncol, 2015, 16(6): 645-655. doi: 10.1016/S1470-2045(15)70126-9
[28]	Chen L, Hu CS, Chen XZ, et al. Adjuvant chemotherapy in patients with locoregionally advanced nasopharyngeal carcinoma: Long-term results of a phase 3 multicentre randomised controlled trial[J]. Eur J Cancer, 2017, 75: 150-158. doi: 10.1016/j.ejca.2017.01.002
[29]	Chan ATC, Hui EP, Ngan RKC, et al. Analysis of plasma Epstein-Barr virus DNA in nasopharyngeal cancer after chemoradiation to identify high-risk patients for adjuvant chemotherapy: A randomized controlled trial[J]. J Clin Oncol, 2018, 31: 3091-3100. http://d.wanfangdata.com.cn/periodical/ChlQZXJpb2RpY2FsRW5nTmV3UzIwMjEwMzAyEiAzYzUzYjY2NzQ5MDFmNzk5MDIwOTQ1NjA4OGM1NTliYxoIcDFhang0OGo%3D
[30]	Tan T, Lim WT, Fong KW, et al. Concurrent chemo-radiation with or without induction gemcitabine, Carboplatin, and Paclitaxel: A randomized, phase 2/3 trial in locally advanced nasopharyngeal carcinoma[J]. Int J Radiat Oncol Biol Phys, 2015, 91(5): 952-960. doi: 10.1016/j.ijrobp.2015.01.002
[31]	Fountzilas G, Ciuleanu E, Bobos M, et al. Induction chemotherapy followed by concomitant radiotherapy and weekly cisplatin versus the same concomitant chemoradiotherapy in patients with nasopharyngeal carcinoma: A randomized phaseⅡ study conducted by the Hellenic Cooperative Oncology Group (HeCOG) with biomarker evaluation[J]. Ann Oncol, 2012, 23(2): 427-435. doi: 10.1093/annonc/mdr116
[32]	Hui EP, Ma BB, Leung SF, et al. Randomized phaseⅡ trial of concurrent cisplatin-radiotherapy with or without neoadjuvant docetaxel and cisplatin in advanced nasopharyngeal carcinoma[J]. J Clin Oncol, 2009, 27(2): 242-249. doi: 10.1200/JCO.2008.18.1545
[33]	Li WF, Chen NY, Zhang N, et al. Concurrent chemoradiotherapy with/without induction chemotherapy in locoregionally advanced nasopharyngeal carcinoma: Long-term results of phase 3 randomized controlled trial[J]. Int J Cancer, 2019, 145(1): 295-305. doi: 10.1002/ijc.32099
[34]	Sun Y, Li WF, Chen NY, et al. Induction chemotherapy plus concurrent chemoradiotherapy versus concurrent chemoradiotherapy alone in locoregionally advanced nasopharyngeal carcinoma: A phase 3, multicentre, randomised controlled trial[J]. Lancet Oncol, 2016, 17(11): 1509-1520. doi: 10.1016/S1470-2045(16)30410-7
[35]	Yang Q, Cao SM, Guo L, et al. Induction chemotherapy followed by concurrent chemoradiotherapy versus concurrent chemoradiotherapy alone in locoregionally advanced nasopharyngeal carcinoma: Long-term results of a phase Ⅲ multicentre randomised controlled trial[J]. Eur J Cancer, 2019, 119: 87-96. doi: 10.1016/j.ejca.2019.07.007
[36]	Cao SM, Yang Q, Guo L, et al. Neoadjuvant chemotherapy followed by concurrent chemoradiotherapy versus concurrent chemoradiotherapy alone in locoregionally advanced nasopharyngeal carcinoma: A phase Ⅲ multicentre randomised controlled trial[J]. Eur J Cancer, 2017, 75: 14-23. doi: 10.1016/j.ejca.2016.12.039
[37]	Zhang Y, Chen L, Hu GQ, et al. Gemcitabine and cisplatin induction chemotherapy in nasopharyngeal carcinoma[J]. N Engl J Med, 2019, 381(12): 1124-1135. doi: 10.1056/NEJMoa1905287
[38]	Tan TH, Soon YY, Cheo T, et al. Induction chemotherapy for locally advanced nasopharyngeal carcinoma treated with concurrent chemoradiation: A systematic review and meta-analysis[J]. Radiother Oncol, 2018, 129(1): 10-17. doi: 10.1016/j.radonc.2018.02.027
[39]	Frikha M, Auperin A, Tao Y, et al. A randomized trial of induction docetaxel-cisplatin-5FU followed by concomitant cisplatin-RT versus concomitant cisplatin-RT in nasopharyngeal carcinoma (GORTEC 2006-02)[J]. Ann Oncol, 2018, 29(3): 731-736. doi: 10.1093/annonc/mdx770
[40]	Lee JY, Sun JM, Oh DR, et al. Comparison of weekly versus triweekly cisplatin delivered concurrently with radiation therapy in patients with locally advanced nasopharyngeal cancer: A multicenter randomized phaseⅡ trial (KCSG-HN10-02)[J]. Radiother Oncol, 2016, 118(2): 244-250. doi: 10.1016/j.radonc.2015.11.030
[41]	Liang H, Li WX, Lv X, et al. Concurrent chemoradiotherapy with 3-weekly versus weekly cisplatin in patients with locoregionally advanced nasopharyngeal carcinoma: A phase 3 multicentre randomised controlled trial (ChiCTR-TRC-12001979)[J]. J Clin Oncol, 2017, 35: 6006. doi: 10.1200/JCO.2017.35.15_suppl.6006
[42]	Ng WT, Tung SY, Lee V, et al. Concurrent-adjuvant chemoradiation therapy for stage Ⅲ-ⅣB nasopharyngeal carcinoma-exploration for achieving optimal 10-year therapeutic ratio[J]. Int J Radiat Oncol Biol Phys, 2018, 101(5): 1078-1086. doi: 10.1016/j.ijrobp.2018.04.069
[43]	Lee AW, Tung SY, Ngan RK, et al. Factors contributing to the efficacy of concurrent-adjuvant chemotherapy for locoregionally advanced nasopharyngeal carcinoma: Combined analyses of NPC-9901 and NPC-9902 trials[J]. Eur J Cancer, 2011, 47(5): 656-666. doi: 10.1016/j.ejca.2010.10.026
[44]	Peng H, Chen L, Zhang Y, et al. Prognostic value of the cumulative cisplatin dose during concurrent chemoradiotherapy in locoregionally advanced nasopharyngeal carcinoma: A secondary analysis of a prospective phase Ⅲ clinical trial[J]. Oncologist, 2016, 21(11): 1369-1376. doi: 10.1634/theoncologist.2016-0105
[45]	Chen YP, Tang LL, Yang Q, et al. Induction chemotherapy plus concurrent chemoradiotherapy in endemic nasopharyngeal carcinoma: Individual patient data pooled analysis of four randomized trials[J]. Clin Cancer Res, 2018, 24(8): 1824-1833. doi: 10.1158/1078-0432.CCR-17-2656
[46]	Petit C, Lee AWM, Carmel A, et al. Network-meta-analysis of chemotherapy in nasopharyngeal carcinoma (MAC-NPC): An update on 8, 221 patients[J]. J Clin Oncol, 2020, 38: 6523. doi: 10.1200/JCO.2020.38.15_suppl.6523
[47]	Lee AWM, Ngan RKC, Ng WT, et al. NPC-0501 trial on the value of changing chemoradiotherapy sequence, replacing 5-fluorouracil with capecitabine, and altering fractionation for patients with advanced nasopharyngeal carcinoma[J]. Cancer, 2020, 126(16): 3674-3688. doi: 10.1002/cncr.32972
[48]	Lee AWM, Tung SY, Ng WT, et al. A multicenter, phase 3, randomized trial of concurrent chemoradiotherapy plus adjuvant chemotherapy versus radiotherapy alone in patients with regionally advanced nasopharyngeal carcinoma: 10-year outcomes for efficacy and toxicity[J]. Cancer, 2017, 123(21): 4147-4157. doi: 10.1002/cncr.30850
[49]	Chen Y, Sun Y, Liang SB, et al. Progress report of a randomized trial comparing long-term survival and late toxicity of concurrent chemoradiotherapy with adjuvant chemotherapy versus radiotherapy alone in patients with stage Ⅲ to IVB nasopharyngeal carcinoma from endemic regions of China[J]. Cancer, 2013, 119(12): 2230-2238. doi: 10.1002/cncr.28049
[50]	Lee AW, Tung SY, Chan AT, et al. A randomized trial on addition of concurrent-adjuvant chemotherapy and/or accelerated fractionation for locally-advanced nasopharyngeal carcinoma[J]. Radiother Oncol, 2011, 98(1): 15-22. doi: 10.1016/j.radonc.2010.09.023
[51]	Chen YP, Chan ATC, Le QT, et al. Nasopharyngeal carcinoma[J]. Lancet, 2019, 394(10192): 64-80. doi: 10.1016/S0140-6736(19)30956-0
[52]	Chen L, Hu CS, Chen XZ, et al. Concurrent chemoradiotherapy plus adjuvant chemotherapy versus concurrent chemoradiotherapy alone in patients with locoregionally advanced nasopharyngeal carcinoma: A phase 3 multicentre randomised controlled trial[J]. Lancet Oncol, 2012, 13(2): 163-171. doi: 10.1016/S1470-2045(11)70320-5
[53]	Wee J, Tan EH, Tai BC, et al. Randomized trial of radiotherapy versus concurrent chemoradiotherapy followed by adjuvant chemotherapy in patients with American Joint Committee on Cancer/International Union against cancer stage Ⅲ and Ⅳ nasopharyngeal cancer of the endemic variety[J]. J Clin Oncol, 2005, 23(27): 6730-6738. doi: 10.1200/JCO.2005.16.790
[54]	Chitapanarux I, Lorvidhaya V, Kamnerdsupaphon P, et al. Chemoradiation comparing cisplatin versus carboplatin in locally advanced nasopharyngeal cancer: Randomised, non-inferiority, open trial[J]. Eur J Cancer, 2007, 43(9): 1399-1406. doi: 10.1016/j.ejca.2007.03.022
[55]	Chitapanarux I, Kittichest R, Tungkasamit T, et al. Two-year outcome of concurrent chemoradiation with carboplatin with or without adjuvant carboplatin/ fluorouracil in nasopharyngeal cancer: A multicenter randomized trial[J]. Curr Probl Cancer, 2021, 45(1): 100620. doi: 10.1016/j.currproblcancer.2020.100620
[56]	Twu CW, Wang WY, Chen CC, et al. Metronomic adjuvant chemotherapy improves treatment outcome in nasopharyngeal carcinoma patients with postradiation persistently detectable plasma Epstein-Barr virus deoxyribonucleic acid[J]. Int J Radiat Oncol Biol Phys, 2014, 89(1): 21-29. doi: 10.1016/j.ijrobp.2014.01.052
[57]	Liu YC, Wang WY, Twu CW, et al. Prognostic impact of adjuvant chemotherapy in high-risk nasopharyngeal carcinoma patients[J]. Oral Oncol, 2017, 64: 15-21. doi: 10.1016/j.oraloncology.2016.11.008
[58]	Chen JH, Huang WY, Ho CL, et al. Evaluation of oral tegafur-uracil as metronomic therapy following concurrent chemoradiotherapy in patients with non-distant metastatic TNM stage Ⅳ nasopharyngeal carcinoma[J]. Head Neck, 2019, 41(11): 3775-3782. doi: 10.1002/hed.25904
[59]	Wang WY, Lin TY, Twu CW, et al. Long-term clinical outcome in nasopharyngeal carcinoma patients with post-radiation persistently detectable plasma EBV DNA[J]. Oncotarget, 2016, 7(27): 42608-42616. http://europepmc.org/articles/PMC5173160/
[60]	Wu Y, Wei XY, Yuan ZL, et al. Phase Ⅱ study of induction chemotherapy followed by concurrent chemoradiotherapy with raltitrexed and cisplatin in locally advanced nasopharyngeal carcinoma[J]. Chin J Cancer Res, 2020, 32(5): 665-672.
[61]	Lee AW, Ng WT, Pan JJ, et al. International guideline for the delineation of the clinical target volumes (CTV) for nasopharyngeal carcinoma[J]. Radiother Oncol, 2018, 126(1): 25-36. doi: 10.1016/j.radonc.2017.10.032
[62]	中国临床肿瘤学会《CSCO鼻咽癌诊疗指南》[M]. 北京: 人民卫生出版社, 2020: 20-34. Chinese society of Clinical Oncology《CSCO guidelines for diagnosis and treatment of nasopharyngeal carcinoma》[M]. Beijing: People's Medical Publishing House, 2020: 20-34.

Cited By

Cited by

Periodical cited type(17)

1.	白芸芸，贾乐，陈福权. 鼻咽癌组织驱动蛋白超家族18B、20A与上皮间质转化标志物及临床病理特征和预后的关系. 中国耳鼻咽喉头颈外科. 2025(01): 1-7 .
2.	王锐，徐丽，杨笑梅，董婕. 中青年鼻咽癌患者心理社会适应能力的影响因素调查及护理研究. 当代护士(中旬刊). 2024(01): 87-91 .
3.	汤中豪，吴宁波. 益气养阴汤联合特瑞普利单抗和GP方案治疗复发晚期鼻咽癌临床观察. 中医药临床杂志. 2024(03): 523-527 .
4.	石先伟，何英，唐组阁，王丽，袁志，任杰，别俊，潘荣强. 离线自适应技术在鼻咽癌放射治疗中的剂量学分析. 西部医学. 2024(03): 447-453 .
5.	吴仁瑞，汪琛，刘超. 同步推量调强放疗在鼻咽癌中的应用效果及对免疫功能的影响. 罕少疾病杂志. 2024(05): 30-32 .
6.	邓智毅，叶祎菁，李定波，武勇进，曾宪海，王再兴. 基于MRI影像组学特征因素预测Ⅱ～Ⅳa期鼻咽癌患者复发转移风险及辅助化疗受益的临床意义. 中国耳鼻咽喉头颈外科. 2024(08): 477-484 .
7.	邓修宁. 化疗联合调强放疗治疗老年（≥65岁）局部晚期鼻咽癌的临床疗效. 广州医药. 2023(04): 40-44 .
8.	张覃晶，周巧，王义荣，姜安梅，文春念. 早期康复训练结合跨理论模型健康教育在行放射治疗鼻咽癌患者中的应用. 中西医结合护理(中英文). 2023(05): 106-108 .
9.	向碧松，郑素芬，陈娴. 放疗前预后营养指数对鼻咽癌病人放疗期口腔黏膜炎发生风险的预测价值. 循证护理. 2023(22): 4122-4126 .
10.	罗焱，谢悦，李晓宇，闫瑾，刘德清，王雨晴，杨丽娜，王颖. 全程热疗治疗鼻咽癌颈部转移淋巴结的疗效及对免疫功能的影响. 重庆医学. 2023(23): 3567-3571 .
11.	张秀莲，吴丽嘉，陈秀莹，曾幼珊，陈楚君. 专业化功能锻炼联合互联网健康指导对鼻咽癌放疗后张口困难患者的影响. 护理实践与研究. 2023(23): 3516-3521 .
12.	何芷怡，车秀娟，张广智. 22例鼻咽癌合并急性脑梗死临床特点分析. 岭南急诊医学杂志. 2023(06): 546-549 .
13.	董艳玲，马国辉，吴楠，李倩，郑加. 养阴解毒汤联合放化疗治疗气阴两虚毒热蕴肺型鼻咽癌晚期疗效观察. 河北中医. 2022(05): 789-792 .
14.	李小芹，沈合松，张菁，刘美伶，王兴，袁筱茜，张久权. IVIM和ASL定量参数在鼻咽癌分期中的临床价值. 肿瘤影像学. 2022(04): 393-402 .
15.	杨荣松，方怡冉，张凯，李泽运. 鼻咽癌组织中还原型辅酶Ⅱ氧化酶4和表皮生长因子受体的表达与调强放疗预后的相关性研究. 中国耳鼻咽喉头颈外科. 2022(11): 693-698 .
16.	周芳亮，蔺婷，刘洁，罗晶婧，何迎春，廖端芳. 小檗碱联合人参皂苷Rg3对鼻咽癌裸鼠移植瘤细胞的干预作用. 中国药学杂志. 2021(18): 1496-1502 .
17.	万霞，卢涛涛，张文. 基于CiteSpace的鼻咽癌放疗患者护理研究的可视化分析. 中华现代护理杂志. 2021(34): 4715-4721 .

Other cited types(7)

Figures(1)

Get Citation

PDF

XML

Article views (2855) PDF downloads (1390) Cited by(24)

Turn off MathJax

Article Contents

Abstract

References

An Interpretation of CSCO/ASCO International Guideline of Chemotherapy in Combination with Radiotherapy for Definitive-intent Treatment of Stage Ⅱ-Ⅳa Nasopharyngeal Carcinoma in 2021